Tien-Li Lee - 09 Feb 2026 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: AARD
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2026, 21:00:15 UTC
Prior SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Sun, as Attorney-in-Fact

Key filing fact

Tien-Li Lee filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 11 Feb 2026.

Key facts

This page summarizes Tien-Li Lee's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 21:00.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001940120 Primary reporting owner

Lee Tien-Li

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO
Signature: /s/ Nelson Sun, as Attorney-in-Fact
Signature date: 11 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AARD transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: -203,851
Change %: -50%
Price: $0.000000
Shares after: 203,851
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 203,851
Exercise price: $13.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.